Search results for " Hepatitis C."

showing 10 items of 174 documents

Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection.

2007

Summary.  Hepatitis C virus (HCV) infection is associated with a significant reduction of health related quality of life (QOL), the causes and mechanisms of which are still unknown. To explore whether treatment history could affect QOL, we examined patients with detectable HCV viraemia who had a different therapeutic background. Two hundred sixty-four consecutive subjects with chronic HCV infection and detectable viraemia were enrolled. Of these, 163 were untreated patients, 43 were relapsers, 58 were nonresponders (NR) to nonpegylated interferon (IFN) therapy. To assess QOL, three self-report instruments were employed: the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLD…

AdultMaleQuestionnairesmedicine.medical_specialtyHealth StatusHepatitis C virusComorbidityAffect (psychology)Chronic liver diseasemedicine.disease_causeliver-specific quality of life nonresponse to treatment physical comorbidity quality of lifeWorld healthVirusQUALITY OF LIFEChronic hepatitisQuality of lifeSurveys and QuestionnairesVirologyInternal medicineHumansMedicineChronicAgedHepatologybusiness.industryHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CComorbidityhumanitiesAdult Aged Comorbidity Female Health Status Hepatitis C; Chronic; drug therapy/virology Humans Interferons; therapeutic use Linear Models Male Middle Aged Quality of Life Questionnairesdrug therapy/virologyInfectious Diseasestherapeutic useHCVLinear ModelsPhysical therapyFemaleInterferonsbusiness
researchProduct

Perihepatic lymph nodes and antiviral response in chronic HCV-associated hepatitis.

2003

To identify predictive factors of response to interferon alpha (IFN-alpha) plus ribavirin therapy in patients with chronic hepatitis C (CHC), the presence of lymphadenopathy (LyA) of the hepatoduodenal ligament and other variables were investigated. A total of 110 patients with histologically proven CHC were enrolled in this study. Ultrasound (US) was performed at the start and end of therapy and 6 months after stopping therapy. At baseline, LyA was present in 35 (43.7%) of 80 patients with alanine aminotransferase (ALT) values and grading was significantly higher than in the LyA-negative group. LyA was more frequent in nonresponders (nonR) than in relapsers (relR) or sustained responders (…

AdultMalemedicine.medical_specialtyAcoustics and UltrasonicsEnd of therapyBiophysicsAlpha interferonGastroenterologyAntiviral Agentschemistry.chemical_compoundInternal medicineRibavirinmedicineHumansUltrasound Lymphadenopathy Chronic hepatitis C Treatment Predictive factors.Radiology Nuclear Medicine and imagingProspective StudiesAlanine aminotransferaseLymph nodeLymphatic DiseasesUltrasonographyHepatitisRadiological and Ultrasound Technologybusiness.industryRibavirinInterferon-alphaHepatoduodenal ligamentHepatitis C ChronicMiddle Agedmedicine.diseasePrognosisSurgerymedicine.anatomical_structureLogistic ModelsTreatment OutcomechemistryDrug Therapy CombinationFemaleLymphbusinessUltrasound in medicinebiology
researchProduct

Anti-hepatitis A virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis

2002

Abstract Background. Patients with chronic hepatitis C infected by hepatitis A virus have a substantial risk of fulminant hepatitis or death, while the course of hepatitis A virus is uncomplicated in most subjects with chronic hepatitis B. Aim. To evaluate the prevalence of anti-hepatitis A virus antibodies and the incidence of hepatitis A virus seroconversion in a nationwide sample of 530 patients with chronic hepatitis B and/or hepatitis C infection initially susceptible to this infection after a follow-up of some years. Results. The overall anti-hepatitis A virus prevalence was 85.7%, with no difference between males and females. By the age of 50 years, almost all patients were found to …

AdultMalemedicine.medical_specialtyAdolescentHepatitis C virusmedicine.disease_causeHepatitis A AntibodiesVirusHepatitis B ChronicSeroepidemiologic StudiesInternal medicinemedicineHumansSeroconversionFulminant hepatitisAgedHepatitis B virusHepatologybusiness.industryIncidenceGastroenterologyHepatitis CHepatitis BHepatitis AHepatitis C ChronicMiddle Agedmedicine.diseaseVirologyChronic liver disease; Hepatitis A virus superinfection; Hepatitis B virus; Hepatitis C virus;ItalyHepatitis A AntibodieFemalebusinessViral hepatitisHepatitis A Virus HumanHuman
researchProduct

Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience

2019

Abstract Aims In 2017 the Italian Drug Agency (Agenzia Italiana del Farmaco, AIFA) revised the criteria for access to therapy for patients with chronic hepatitis C as part of a three-year plan to eradicate HCV. We conducted a Delphi study to determine strategies to identify and treat patients with HCV and to develop through a shared pathway, a model to manage patient referral and optimize prescription center capacity with the overall aim of increasing access to therapy. Methods The process took place in two phases – Phase I (January 2017), before the criteria for treatment of HCV were revised and Phase II (May 2017) when AIFA developed a framework for the eradication of HCV infection in Ita…

AdultMalemedicine.medical_specialtyDelphi TechniqueGeneral PracticeDelphi methodDelphi methodAntiviral AgentsDrug PrescriptionsHealth Services AccessibilityMedication AdherencemodelsPatient referralTreatment targetsChronic hepatitismedicineHumansdelphi method; direct-acting antivirals; disease eradication; hepatitis c virus; adult; aged; antiviral agents; disease eradication; drug prescriptions; female; general practice; health care surveys; health services accessibility; hepatitis c chronic; humans; italy; male; medication adherence; middle aged; models theoretical; quality Improvement; referral and consultation; delphi techniquehepatitis cMedical prescriptiontheoreticalReferral and Consultationdirect-acting antiviralsAgedHepatitisdirect-acting antiviralHepatologyDisease Eradicationbusiness.industryHepatitis C virusGastroenterologyDrug agencyHepatitis C ChronicMiddle AgedModels Theoreticalmedicine.diseaseQuality ImprovementchronicItalyHealth Care SurveysFamily medicineFemaledisease eradicationbusiness
researchProduct

Combination therapy with amantadine and interferon in naı̈ve patients with chronic hepatitis C: meta-analysis of individual patient data from six cli…

2003

Abstract Background/Aims In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results. We performed a meta-analysis of the individual patient's data from previous studies. Methods Nine hundred and seventy-two patients from six European centres were evaluated by means of individual patient meta-analysis, using mixed models with centres and the centre–treatment interaction fitted as random variables. Results At the end of therapy, virological responses were 38.5% (95% CI 34.1–42.8) after INF and AMA, and 29.5% (95% CI 25.5–33.6) after INF alone (P=0.003). Sustained response occurred in 1…

AdultMalemedicine.medical_specialtyGenotypeCombination therapyHepacivirusAntiviral AgentsGastroenterologymeta-analysilaw.inventionchemistry.chemical_compoundPharmacotherapyRandomized controlled triallawInternal medicineparasitic diseasesAmantadinemedicinechronic hepatitis CHumansAgedRandomized Controlled Trials as TopictherapyDose-Response Relationship DrugHepatologybusiness.industryRibavirinAmantadineAlanine TransaminaseinterferonHepatitis CHepatitis C ChronicMiddle AgedViral Loadrandomized clinical trialmedicine.diseaseClinical trialTreatment OutcomechemistryImmunologyDrug Therapy CombinationFemaleInterferonsbusinessViral loadmedicine.drugJournal of Hepatology
researchProduct

Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin

2008

Guidelines for the treatment of patients infected with hepatitis C virus of genotypes 2 and 3 (HCV-2 and HCV-3, respectively) recommend a 24-week course of Peg-interferon (Peg-IFN) alpha-2a combined with ribavirin, despite 50% of patients in registration trials attaining a sustained virologic response (SVR) following Peg-IFN alpha-2a monotherapy. The aim of this study was to delineate patient characteristics that might help to identify individuals likely to benefit from ribavirin discontinuation. One hundred and forty-four HCV-2- and HCV-3-infected patients initiated Peg-IFN alpha-2a (180 microg/week) and ribavirin (1000 or 1200 mg/day); those with viral clearance at week 4 were randomized …

AdultMalemedicine.medical_specialtyGenotypeCombination therapyHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeChronic hepatitis CAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundVirologyInternal medicineRibavirinmedicineHumansRapid Virologic ResponseHepatologyPeg-interferonbusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis CMiddle AgedViral Loadmedicine.diseaseHepatitis CRecombinant Proteinsdigestive system diseasesDiscontinuationClinical trialTreatment OutcomeInfectious DiseasesWithholding TreatmentchemistryImmunologyChronic hepatitis C; Clinical trial; Peg-interferon; Ribavirin;FemaleViral hepatitisbusinessViral load
researchProduct

Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients

2012

Background: Hepatitis C virus infection is characterised by enhanced oxidative stress, which can be measured quantitatively by plasma oxysterol concentration. These molecules may affect lipid metabolism through the activation of Liver X Receptors. Hepatitis C virus exploits host lipid metabolism to facilitate its replication and diffusion. In our study we aimed to evaluate and highlight the potential pathogenetic role of oxysterols, 7-ketocholesterol and 7-β-hydroxycholesterol, in hepatitis C virus-related lipid dysmetabolism. Methods: The study was performed in 42 patients with chronic hepatitis C (93% genotype 1b) and 38 non-alcoholic fatty liver disease patients. Plasma oxysterols 7-keto…

AdultMalemedicine.medical_specialtyOxysterolHepatitis C virusHepacivirusIsotope dilutionmedicine.disease_causechronic hepatitis c infection; lipid metabolism; non-alcoholic fatty liver disease; oxidative stressNon-alcoholic Fatty Liver DiseaseInternal medicinemedicinepolycyclic compoundsoxysterol hcv nafldHumansoxysterols sterols cholesterol mass spectrometry metabolomicsLiver X receptorKetocholesterolsHepatologybusiness.industryFatty liverGastroenterologyLipid metabolismHepatitis CCholesterol LDLMiddle Agedmedicine.diseaseHepatitis CChronic hepatitis C infectionHydroxycholesterolsFatty LiverOxidative StressEndocrinologyLipid metabolismBiochemistryMultivariate AnalysisLinear Modelslipids (amino acids peptides and proteins)FemalebusinessOxidative stress
researchProduct

Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.

2006

: Background/Aim: Liver steatosis (LS) has been variably associated with chronic hepatitis C (CHC) but whether it affects sustained virological response to antiviral treatment and by what mechanisms is a question still under debate, at least for some genotypes. The aim of this work was to assess the frequency of LS, its relationship with host and viral factors and to what extent it can influence the response to antiviral combination therapy with pegylated interferon (INF)+ribavirin in a group of patients with CHC from a single center. Patients: One hundred and twelve patients with histologically proven CHC were treated with Peg INF-α 2a 180 μg a week subcutaneously for 48 weeks plus ribavir…

AdultMalemedicine.medical_specialtyPathologyAgingCombination therapyGenotypeHepatitis C virusantiviral treatmentHepacivirusInterferon alpha-2Single Centermedicine.disease_causeGastroenterologyAntiviral AgentsSeverity of Illness IndexBody Mass IndexPolyethylene Glycolsliver steatosischemistry.chemical_compoundPegylated interferonInternal medicineGenotypeRibavirinmedicinechronic hepatitis CHumansAspartate AminotransferasesHepatologybusiness.industryRibavirinInterferon-alphaAlanine Transaminasegamma-GlutamyltransferaseHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsFatty LiverTreatment OutcomechemistryLiverDrug Therapy CombinationFemaleSteatosisbusinessBody mass indexmedicine.drugLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Ultrasound detection of abdominal lymphadenomegaly in subjects with hepatitis C virus infection and persistently normal transaminases: a predictive i…

1998

The indications for liver biopsy in anti-HCV-positive patients with persistently normal alanine aminotransferase levels are not clearly established. Recent studies have correlated the presence of abdominal lymphoadenomegaly with disease severity in patients with chronic hepatitis C. Our study aimed to evaluate the frequency of abdominal lymphoadenomegaly in an anti-HCV positive blood donor population with persistently normal alanine aminotransferase and the relationship of abdominal lymphoadenomegaly with the severity of liver changes.Eighty-six anti-HCV positive blood donors (58 M, 28 F) with normal alanine aminotransferase were followed up for a median of 31 months (range 12-50). To evalu…

AdultMalemedicine.medical_specialtyPathologySettore MED/09 - Medicina InternaLogistic ModelAdolescentPrognosiHepatitis C virusHepacivirusBiopsyPopulationBlood Donorsmedicine.disease_causeGastroenterologyRegression AnalysiInternal medicineAbdomenmedicineHumanseducationLymphatic Diseasesabdominal lymph nodes; chronic hepatitis c; normal transaminase; ultrasoundUltrasonographyeducation.field_of_studyHepatologymedicine.diagnostic_testbiologybusiness.industryUltrasoundAlanine TransaminaseHepatitis C AntibodiesHepatitis C ChronicMiddle Agedbiology.organism_classificationPrognosismedicine.anatomical_structureLogistic ModelsLiverLiver biopsyAbdomenRegression AnalysisFemaleViral diseaseLiver functionLymphatic DiseaseHepatitis C AntibodiebusinessHumanJournal of hepatology
researchProduct

Interferon as treatment for acute hepatitis C

1996

The efficacy of short-course (three months), low-dose (3 million units three times a week) interferon as treatment for acute hepatitis C was evaluated in a meta-analysis of controlled trials. Nine studies (five randomized and four nonrandomized) found by MEDLINE search were eligible for analysis. The outcomes assessed were the rate of patients with normal serum aminotransferases (all trials) and without HCV RNA in blood (five trials) after posttreatment follow-up. Eight trials compared interferon to no treatment, and one compared different schedules of interferon. The methodological quality of the studies was high. However, all trials had been planned for a short-term evaluation based on bi…

AdultMalemedicine.medical_specialtyPhysiologymedicine.medical_treatmentHepacivirusGastroenterologyInterferonInternal medicinemedicineHumansClinical significanceProspective cohort studyHepatologybusiness.industryGastroenterologyInterferon-alphaInterferon-betaImmunotherapyMiddle AgedHepatologyHepatitis CConfidence intervalMeta-analysisAcute DiseaseImmunologyRNA ViralFemaleControlled Clinical Trials as TopicAcute hepatitis CViral diseasebusinessmedicine.drugDigestive Diseases and Sciences
researchProduct